Precision BioSciences (DTIL) AI Stock Analysis

• Market Cap: $55.77M
• Dividend Yield: N/A
• Average Volume (3M): 77.15K
• Price to Earnings (P/E): 2.4
• Beta (1Y): 1.16
• Revenue Growth: -11.11%
• EPS Growth: 79.74%
• Country: US
• Employees: 108
• Sector: Healthcare
• Sector Strength: 59
• Industry: Biotechnology
• EPS (TTM): -2.21
• Shares Outstanding: 11,088,234
• 10 Day Avg. Volume: 84,551
• 30 Day Avg. Volume: 77,150
• PEG Ratio: 0.19
• Price to Book (P/B): 4.76
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -26.07
• Enterprise Value/Market Cap: -0.78
• Enterprise Value/Revenue: -0.15
• Enterprise Value/Gross Profit: -0.85
• Enterprise Value/Ebitda: -1.08
• 1Y Price Target: $34.33
• Price Target Upside: 600.61% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 51 Neutral
• Price Target: $5.00 ▲(2.04%Upside)

The overall stock score reflects significant financial challenges, including negative earnings and declining equity, which weigh heavily on the assessment. However, recent positive corporate events related to key program advancements provide some optimism for future growth potential.

Positive Factors

Clinical Validation

Partnered programs continue to validate ARCUS, most notably with iECURE’s ECUR-506 achieving a complete clinical response in the first OTC-deficiency patient dosed.

Market Potential

The company's strategy for PBGENE-DMD could address up to 60% of DMD cases, which is significantly higher than existing treatments.

Regulatory Progress

The FDA has cleared the IND application for PBGENE-HBV in chronic HBV, allowing for enrollment to begin in the U.S. sites.

Negative Factors

Resource Allocation

The development of PBGENE-3243 has been paused to preserve cash and fund other clinical programs.

Safety Concerns

There is an expectation that future updates at higher doses with 2-3 administrations will have a greater degree of toxicity.

Precision BioSciences Business Overview & Revenue Model

Company Description

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

How the Company Makes Money

Precision BioSciences generates revenue through various channels, including partnerships and collaborations with other biotechnology and pharmaceutical companies. These partnerships often involve licensing agreements for the use of its ARCUS technology, leading to milestone payments and royalties. Additionally, the company aims to commercialize its own therapeutic products, which could provide revenue from product sales. Significant factors contributing to its earnings include successful development and commercialization of therapies, as well as strategic alliances that leverage its genome editing expertise.

Precision BioSciences Financial Statement Overview

Summary

Precision BioSciences faces significant financial challenges, particularly in profitability and cash flow. Despite a strong cash position, negative earnings, declining equity, and inconsistent revenue growth are major concerns.

Income Statement

The company shows fluctuating revenue with recent declines, as seen in the TTM (Trailing-Twelve-Months) figures. Gross profit margin is solid, but negative EBIT and net income margins indicate operational and profitability challenges. Revenue growth has been inconsistent with a significant drop in the latest TTM period.

Balance Sheet

The company maintains a strong cash position relative to debt, indicating low leverage. However, stockholders' equity has decreased over time, and the equity ratio reflects a relatively weak capital structure. Debt-to-equity ratio is manageable, but the decline in equity is concerning.

Cash Flow

Free cash flow remains negative, with little improvement over time. Operating cash flow is consistently negative, indicating challenges in core business profitability. The operating cash flow to net income ratio is unfavorable, reflecting cash generation issues.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
51.14M	68.70M	48.73M	25.10M	115.53M	24.29M
	Gross Profit
51.14M	68.70M	40.47M	16.09M	115.53M	24.29M
	EBIT
-44.09M	-26.16M	-43.74M	-100.37M	-39.40M	-109.83M
	EBITDA
-16.57M	13.53M	-32.04M	-62.79M	-20.27M	-99.19M
	Net Income Common Stockholders
-21.99M	7.17M	-61.32M	-122.91M	-30.92M	-109.01M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
77.22M	86.31M	116.68M	189.58M	143.66M	89.80M
	Total Assets
124.41M	136.39M	159.78M	238.17M	211.50M	150.16M
	Total Debt
1.36M	30.05M	31.27M	27.04M	9.11M	10.52M
	Net Debt
-75.86M	-55.85M	-85.41M	-162.54M	-134.55M	-79.28M
	Total Liabilities
75.07M	80.00M	140.92M	177.74M	120.33M	105.73M
	Stockholders Equity
49.34M	56.39M	18.86M	60.43M	91.17M	44.42M
Cash Flow		Free Cash Flow
-58.74M	-58.70M	-86.39M	-49.07M	-16.66M	-92.42M
	Operating Cash Flow
-58.52M	-58.45M	-84.11M	-45.75M	-10.85M	-87.39M
	Investing Cash Flow
-503.00K	-215.00K	5.83M	-3.32M	-5.80M	-5.03M
	Financing Cash Flow
21.04M	50.45M	5.39M	94.98M	70.52M	1.33M

Precision BioSciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DTIL, the sentiment is Negative. The current price of 4.9 is below the 20-day moving average (MA) of 4.96, below the 50-day MA of 5.02, and below the 200-day MA of 6.35, indicating a bearish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 46.07 is Neutral, neither overbought nor oversold. The STOCH value of 20.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DTIL.

Precision BioSciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTMX	68 Neutral	$433.25M	5.55	-58.97%	―	23.81%	146.45%
Sector *	54 Neutral	$5.38B	3.27	-45.10%	3.30%	16.81%	0.02%
DTIL	51 Neutral	$55.77M	2.40	-50.81%	―	-11.11%	79.74%
BLUE	51 Neutral	$48.67M	―	-546.55%	―	127.51%	56.94%
IKNA	41 Neutral	$66.11M	―	-30.49%	―	-100.00%	37.59%
ACRV	36 Underperform	$39.82M	―	-62.41%	―	―	10.84%
ACET	27 Underperform	$64.51M	―	-55.83%	―	―	59.75%

Precision BioSciences Corporate Events

Precision BioSciences Holds Annual Stockholder Meeting

On May 28, 2025, Precision BioSciences, Inc. held its annual meeting of stockholders, where 71% of the common stock was represented. The meeting resulted in the election of Kevin J. Buehler and Shari Lisa Piré as Class III directors, and the approval of several proposals, including the ratification of Deloitte & Touche LLP as the independent accounting firm and an annual advisory vote on executive compensation. However, a proposal to amend the Certificate of Incorporation regarding officer exculpation did not pass as it failed to meet the required voting threshold.

The most recent analyst rating on (DTIL) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.

Precision BioSciences Reports Q1 Results and Business Update

On May 15, 2025, Precision BioSciences reported its first quarter financial results and provided a business update, highlighting new clinical data for its ARCUS-based programs. The company announced progress in its ELIMINATE-B trial for PBGENE-HBV, a potential curative treatment for chronic Hepatitis B, which received Fast Track Designation from the FDA. Additionally, Precision is accelerating its PBGENE-DMD program for Duchenne’s Muscular Dystrophy, aiming to file an IND/CTA in 2025, with clinical data expected in 2026. The company plans to pause the development of PBGENE-3243 to focus resources on these programs.

The most recent analyst rating on (DTIL) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.

Precision BioSciences Accelerates PBGENE-DMD Program for DMD

On May 14, 2025, Precision BioSciences announced the acceleration of its PBGENE-DMD program, a first-in-class in vivo gene editing approach for Duchenne Muscular Dystrophy (DMD), highlighting preclinical evidence at the ASGCT Annual Meeting. The program aims to address the significant unmet need for DMD treatments by restoring the body’s production of functional dystrophin protein, potentially offering a durable intervention for most patients. Precision plans to submit an IND and/or CTA in 2025, with clinical data expected in 2026, while pausing development of PBGENE-3243 to focus on advancing PBGENE-DMD and PBGENE-HBV through Phase 1 clinical results.

The most recent analyst rating on (DTIL) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.